Characterization of lung cancers in patients with BRCA germline variants: A multicenter series

Archive ouverte

Sanchis-Borja, Mateo | Fallet, Vincent | Fabre, Elisabeth | Wislez, Marie | Culine, Stéphane | Zalcman, Gérard | Spano, Jean-Philippe | Buffet, Nathalie Chabbert | Coulet, Florence | Benusiglio, Patrick, R | Cadranel, Jacques

Edité par CCSD ; Elsevier -

International audience. Introduction: BRCA1 and BRCA2 (BReast CAncer susceptibility genes) are two tumor-suppressor genes associated with the hereditary breast and ovarian cancer susceptibility syndrome. Recent studies also suggest an increased lung adenocarcinoma risk in carriers. Methods: We conducted a multi-center retrospective study in 18 different French pulmonology and/or oncology departments on medico-administrative and clinical data prospectively collected in the Clinical Data Warehouse (CDW) of Greater Paris University Hospitals (Assistance Publique-Hôpitaux de Paris, AP-HP). Clinical characteristics and outcomes of patients with LC and a previously known BRCA1/2gl variant were retrospectively evaluated. Results: 17 patients with LC and known BRCA1/2gl variant were included. Patients were most women, former smokers with localized disease and BRCA2 variants. All LC were adenocarcinoma. For patients with medical history of cancer, median time from the first cancer in the BRCA spectrum and the LC occurrence was 20 years. Median disease-free survival (DFS) and overall survival (OS) in localized tumor (Stage I and II) was not reached and 78.6 months, respectively. In advanced cancer (Stade III and IV) median progression free survival was 9.7 months and median OS was 17.8 months. Univariate OS and DFS/PFS analyses by BRCA status did not find significant differences. Conclusion: Results seem to show particular LC features in carriers of BRCA2 variants: adenocarcinoma subtype, woman, former or non-smoker.

Suggestions

Du même auteur

Lung cancer is also a hereditary disease

Archive ouverte | Benusiglio, Patrick, R | CCSD

International audience. Pathogenic genetic variants (formerly called mutations) present in the germline of some individuals are associated with a clinically relevant increased risk of developing lung cancer. These g...

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients

Archive ouverte | Gounant, Valérie | CCSD

International audience. Anti-PD-1 antibodies prolong survival of performance status (PS) 0–1 advanced non-small-cell lung cancer (aNSCLC) patients. Their efficacy in PS 3–4 patients is unknown. Conse- cutive PS 3–4 ...

Emerging cancer risks in BRCA2 pathogenic germline variant carriers. Risques émergents chez les porteurs de variants pathogènes BRCA2

Archive ouverte | Benusiglio, Patrick, R | CCSD

International audience

Chargement des enrichissements...